• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Incyte to Present Numerous Studies at EADV 2023


Late-breaking data, oral presentations, and ePosters from Incyte’s dermatology portfolio will be presented in Berlin, Germany, October 11-14.



Incyte recently announced that numerous studies from its dermatology portfolio have been accepted for presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2023 meeting October 11-14 in Berlin, Germany.1

Incyte’s key abstracts include:

Late-Breaking Oral Presentations


Efficacy and Safety of Povorcitinib for Extensive Vitiligo: 52-Week Results from a Double-Blinded, Placebo-Controlled, Dose-Ranging Phase 2b Study (Abstract #6749. Session: D1T01.1A: Late Breaking News. Wednesday, October 11, 8:15 a.m. – 8:30 a.m. ET)

Efficacy of Prolonged Ruxolitinib Cream Treatment for Vitiligo Among Patients with Limited or No Initial Response at 6 Months (Abstract #6479. Session: D1T01.1I: Late Breaking News. Wednesday, October 11, 10:30 a.m. – 10:45 a.m. ET)

Atopic Dermatitis

A Phase 3 Study of Ruxolitinib Cream in Children Aged 2–<12 Years with Atopic Dermatitis (TRuE-AD3): 8-Week Analysis (Abstract #6746. Session: D3T01.3I: Late Breaking News. Friday, October 13, 10:30 a.m. – 10:45 a.m. ET)

Oral Presentations

Hidradenitis Suppurativa

Baseline Demographic and Disease Characteristics Associated with Achieving HiSCR with Povorcitinib: Secondary Analysis from a Phase 2, Randomized, Placebo-Controlled Clinical Trial (Abstract #2803. Session: FC02.1: Free Communications II. Thursday, October 12, 4:15 a.m. – 4:25 a.m. ET)

Impact of Povorcitinib on DLQI and DLQI Subdomains in Patients with Hidradenitis Suppurativa: Results from a Randomized, Placebo-Controlled Phase 2 Study (Abstract #2795. Session: FC02.2: Free Communications II. Thursday, October 12, 4:25 a.m. – 4:35 a.m. ET)



Effect of Ruxolitinib Cream on VASI-50 Achievement by Body Region Through Week 104 in Patients with Vitiligo: Analysis of the TRuE-V Long-Term Extension Phase 3 Study (Abstract #926)

Efficacy and Safety of Ruxolitinib Cream Through Week 104 in Patients with Vitiligo: Subgroup Analysis of the TRuE-V Long-Term Extension Phase 3 Study (Abstract #927)

Characterization and Treatment of Acne that Occurred Among Individuals with Vitiligo who Applied Ruxolitinib Cream in Two Randomized Phase 3 Trials (Abstract #2595)

Depression and Depressive Symptoms Among Persons Living with Vitiligo: Findings from the Global VALIANT Survey (Abstract #2572)

Treatment Satisfaction, Breaks and Cessation Among Patients Living with Vitiligo: Findings from the Global VALIANT Survey (Abstract #2579)

Retrospective Database Analysis on the Treatment Patterns in Patients with Vitiligo in Quebec, Canada (Abstract #2591)

Epidemiology and Comorbidity of Patients with Vitiligo in Germany (Abstract #3072)

Atopic Dermatitis

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged ≥2 years to <12 Years with Atopic Dermatitis: 8-Week Analysis (Abstract #2551)

Rapid, Substantial and Sustained Reduction of Itch in Adults with Atopic Dermatitis Applying Ruxolitinib Cream — Clinical and Translational Results from the Open-Label Phase 2 SCRATCH-AD Study (Abstract #2813)

Click here to view the full EADV program.

“We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, MD, PhD, group vice president of inflammation & autoimmunity at Incyte, in the news release. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community."

Earlier this year, Incyte presented multiple abstracts at the 2023 American Academy of Dermatology Annual Meeting, which included vitiligo updates on the phase 3 TruE-V trials of ruxolitinib cream and the safety and efficacy data from a phase 2b study of povorcitinib.2


  1. Incyte to present multiple studies from dermatology portfolio at 2023 European Academy Of Dermatology And Venereology (EADV) Congress. Incyte. News Release. September 29, 2023. Accessed September 29, 2023. https://investor.incyte.com/news-releases/news-release-details/incyte-present-multiple-studies-dermatology-portfolio-2023
  2. Multiple abstracts from Incyte’s growing dermatology portfolio featured at American Academy of Dermatology (AAD) Annual Meeting. Incyte. News Release. March 6, 2023. Accessed September 29, 2023. https://investor.incyte.com/news-releases/news-release-details/multiple-abstracts-incytes-growing-dermatology-portfolio
Related Videos
© 2023 MJH Life Sciences

All rights reserved.